Preclinical Testing News and Research

RSS

New report outlines strategies for regenerating retinal ganglion cells

A new report gives recommendations for regenerating retinal ganglion cells (RGCs), crucial neurons in the back of the eye that carry visual information to the brain.

31 Mar 2017

UAB chemists design microcapsules for guided drug delivery system to target solid tumors

Chemists at the University of Alabama at Birmingham have designed triple-threat cancer-fighting polymer capsules that bring the promise of guided drug delivery closer to preclinical testing.

30 Mar 2017

Researchers identify attractive drug candidate to target glioma tumors

In a paper published today in Cancer Research, researchers: 1) identify a biomarker enzyme associated with aggressive glioma brain tumors, 2) reveal the regulatory mechanism for that enzyme, and 3) demonstrate potent efficacy, using a mouse model of glioma, for a small molecule inhibitor they have developed.

16 Dec 2016

New self-regulating smart patch releases blood-thinning drugs when necessary

An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occurrence of dangerous blood clots - a condition known as thrombosis.

29 Nov 2016

New UCF technology for destroying metastatic breast cancer cells licensed for clinical trials

A University of Central Florida cancer researcher has discovered a way to kill spreading breast cancer cells and her new technology has generated a licensing agreement that will accelerate the therapy's path to clinical trials.

25 Aug 2016

Scientists receive $2.4 million grant to advance stem cell therapy for Parkinson's disease

Scientists at The Scripps Research Institute and Scripps Clinic have received a grant of nearly $2.4 million from the California Institute for Regenerative Medicine to support safety and quality tests of a potential stem cell therapy for Parkinson's disease.

22 Jul 2016

New IRAP inhibitors may hold promise for improving cognitive functions in animal models

Researchers have discovered three new inhibitors of insulin-regulated aminopeptidase (IRAP), compounds shown to improve cognitive functions in animal models of human disorders.

2 Jun 2016

Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.

24 May 2016

New molecule has potential to prolong life of cystic fibrosis patients

Scientists at Queen's University Belfast have discovered a new molecule which has the potential to prolong the life of individuals with cystic fibrosis (CF).

12 May 2016

Scientists develop mouse model to gain new insights into genetic mechanisms underlying AML

A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets.

31 Mar 2016

Research describes first new mouse model for Zika infection in decades

Efforts to combat the rapid spread of Zika virus got a boost this week as researchers at the University of Texas Medical Branch, Galveston (UTMB) announced the first peer-reviewed publication of a mouse model for Zika infection reported in decades.

30 Mar 2016

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

The Centre for Addiction and Mental Health and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression.

1 Mar 2016

SRI Biosciences, SCI collaborate to develop novel compounds to treat multiple forms of cancer

A new collaborative program between scientists at SRI Biosciences, a division of SRI International, and physician-researchers from Stanford Cancer Institute will pursue development of novel compounds to treat multiple forms of cancer and other conditions.

8 Dec 2015

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats.

13 Nov 2015

GHIT Fund invests $10.7 million to fight malaria, TB, leishmaniasis and dengue

The Global Health Innovative Technology Fund, which in the last two years has invested US$43 million to develop innovative tools for fighting diseases worldwide, today announced it is investing $10.7 million at multiple points in the product development pipeline to seek new interventions for malaria, tuberculosis (TB), leishmaniasis and dengue.

5 Nov 2015

New initiative launched to accelerate search for effective HIV vaccine

A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins today. Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA in a focused effort to develop protective and therapeutic HIV vaccines.

2 Nov 2015

First patients receive doses of antisense drug for Huntington's disease

The first few patients have received doses of an experimental RNA-targeting drug for Huntington's disease, it was announced today.

20 Oct 2015

ATA announces first-year research grants to support promising young researchers

The American Thyroid Association (ATA) is pleased to announce the awarding of first-year grants to support two young researchers selected from among a pool of applicants who proposed projects that will contribute novel insights and information with the potential to lead to new drug targets and therapeutic strategies to improve the treatment of thyroid cancer and patient outcomes.

13 Oct 2015

Pabetalone (RVX-208) to be tested in proof-of-concept pilot study in complement mediated diseases

Resverlogix Corp. announced today the commencement of an Orphan Disease Program specific for Complement Mediated Diseases. New data generated by Resverlogix has demonstrated that BET inhibition by apabetalone (RVX-208) has effects on multiple biological pathways that underlie disease pathology.

24 Sep 2015

Stanford researchers successfully defeat C. difficile bacteria

Stanford University School of Medicine scientists successfully defeated a dangerous intestinal pathogen, Clostridium difficile, with a drug targeting its toxins rather than its life.